Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Di Meglio

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Critical Reviews in Oncology/Hematology|December 14, 2020
Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic reviewPietro Lapidari, Ines Vaz-Luis, Antonio Di Meglio
Vaccine|February 4, 2024
Genomic and transcriptomic analysis of the recent Mpox outbreakFederico M Giorgi, Daniele Pozzobon, Antonio Di Meglio, et al.
Current Opinion in Oncology|August 30, 2021
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapyAntonio Di Meglio, Davide Soldato, Daniele Presti, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2021
Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast CancersInes Vaz-Luis, Prudence A Francis, Antonio Di Meglio, et al.
BMC Cancer|August 28, 2014
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literatureAntonio Di Meglio, Pier Vitale Nuzzo, Francesco Ricci, et al.
Tumori|June 6, 2015
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case reportCarlo Messina, Antonio Di Meglio, Pier Vitale Nuzzo, et al.
Tumori|September 30, 2015
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case reportCarlo Messina, Antonio Di Meglio, Pier Vitale Nuzzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Reply to S. YangDavide Soldato, Ines Vaz-Luis, Antonio Di Meglio, et al.
The Lancet Regional Health. Europe|September 24, 2025
Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studiesHugo Jourdain, Antonio Di Meglio, Imène Mansouri, et al.
Oncology Research and Treatment|June 9, 2020
Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor SubtypeElisa Zanardi, Antonio Di Meglio, Chiara Boccardo, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Critical Reviews in Oncology/Hematology|December 14, 2020
Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic reviewPietro Lapidari, Ines Vaz-Luis, Antonio Di Meglio
Vaccine|February 4, 2024
Genomic and transcriptomic analysis of the recent Mpox outbreakFederico M Giorgi, Daniele Pozzobon, Antonio Di Meglio, et al.
Current Opinion in Oncology|August 30, 2021
Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapyAntonio Di Meglio, Davide Soldato, Daniele Presti, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2021
Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast CancersInes Vaz-Luis, Prudence A Francis, Antonio Di Meglio, et al.
BMC Cancer|August 28, 2014
Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literatureAntonio Di Meglio, Pier Vitale Nuzzo, Francesco Ricci, et al.
Tumori|June 6, 2015
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case reportCarlo Messina, Antonio Di Meglio, Pier Vitale Nuzzo, et al.
Tumori|September 30, 2015
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case reportCarlo Messina, Antonio Di Meglio, Pier Vitale Nuzzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Reply to S. YangDavide Soldato, Ines Vaz-Luis, Antonio Di Meglio, et al.
The Lancet Regional Health. Europe|September 24, 2025
Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studiesHugo Jourdain, Antonio Di Meglio, Imène Mansouri, et al.
Oncology Research and Treatment|June 9, 2020
Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor SubtypeElisa Zanardi, Antonio Di Meglio, Chiara Boccardo, et al.
Pageof 9